STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder Agreement follows STALICLA’s recent in-licencing of mavoglurant from Novartis Geneva, Switzerland – 8 March 2023, STALICLA SA, a clinical stage biotech…